| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 25, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 25, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2025 | $2.50 | Overweight → Neutral | Piper Sandler |
| 3/10/2025 | $17.00 | Buy | D. Boral Capital |
| 12/11/2024 | $17.00 → $7.50 | Buy → Neutral | Citigroup |
| 6/4/2024 | $12.00 | Buy | Lake Street |
| 2/23/2024 | $16.00 → $14.00 | Overweight → Equal Weight | Wells Fargo |
| 9/5/2023 | $18.00 | Buy | Craig Hallum |
| 2/27/2023 | $10.00 → $15.00 | Equal Weight → Overweight | Wells Fargo |
| 1/3/2023 | $8.00 | Neutral → Underperform | BofA Securities |
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the "Grant Date"), Pulmonx granted equity awards under its 2025 Inducement Plan (the "Inducement Plan") to 17 individuals hired by Pulmonx in the first two quarters of 2026. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of t
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basisDelivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decreaseDelivered $7.3 million in international revenue in the first quarter of 2026, representing a 12% year-over-year decrease
REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial Va
10-Q - Pulmonx Corp (0001127537) (Filer)
8-K - Pulmonx Corp (0001127537) (Filer)
DEFA14A - Pulmonx Corp (0001127537) (Filer)
Piper Sandler downgraded Pulmonx from Overweight to Neutral and set a new price target of $2.50
D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00
Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously
4 - Pulmonx Corp (0001127537) (Issuer)
4 - Pulmonx Corp (0001127537) (Issuer)
4 - Pulmonx Corp (0001127537) (Issuer)
4 - Pulmonx Corp (0001127537) (Issuer)
4 - Pulmonx Corp (0001127537) (Issuer)
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of
LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir
SC 13G/A - Pulmonx Corp (0001127537) (Subject)
SC 13G/A - Pulmonx Corp (0001127537) (Subject)
SC 13G/A - Pulmonx Corp (0001127537) (Subject)
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026. Recent Highlights Achieved worldwide revenue of $20.6 million in the first quarter of 2026, a 9% decrease over the same period last year and a decrease of 12% on a constant currency basisDelivered $13.3 million in U.S. revenue in the first quarter of 2025, representing a 7% year-over-year decreaseDelivered $7.3 million in international revenue in the first quarter of 2026, representing a 12% year-over-year decrease
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basisRealized gross margin of 78% in the fourth quarter of 2025 and 7